ATE349198T1 - Zusammensetzung und verfahren zur krebs-antigen- immuntherapie - Google Patents

Zusammensetzung und verfahren zur krebs-antigen- immuntherapie

Info

Publication number
ATE349198T1
ATE349198T1 AT00968692T AT00968692T ATE349198T1 AT E349198 T1 ATE349198 T1 AT E349198T1 AT 00968692 T AT00968692 T AT 00968692T AT 00968692 T AT00968692 T AT 00968692T AT E349198 T1 ATE349198 T1 AT E349198T1
Authority
AT
Austria
Prior art keywords
patient
lymphocytes
composition
effector
cancer antigen
Prior art date
Application number
AT00968692T
Other languages
English (en)
Inventor
Gary W Wood
Original Assignee
Tvax Biomedical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tvax Biomedical Llc filed Critical Tvax Biomedical Llc
Application granted granted Critical
Publication of ATE349198T1 publication Critical patent/ATE349198T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46432—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/56—Kidney

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT00968692T 1999-10-05 2000-10-05 Zusammensetzung und verfahren zur krebs-antigen- immuntherapie ATE349198T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/412,681 US6406699B1 (en) 1999-10-05 1999-10-05 Composition and method of cancer antigen immunotherapy

Publications (1)

Publication Number Publication Date
ATE349198T1 true ATE349198T1 (de) 2007-01-15

Family

ID=23634000

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00968692T ATE349198T1 (de) 1999-10-05 2000-10-05 Zusammensetzung und verfahren zur krebs-antigen- immuntherapie

Country Status (11)

Country Link
US (2) US6406699B1 (de)
EP (1) EP1225870B1 (de)
AT (1) ATE349198T1 (de)
AU (1) AU7856700A (de)
CA (1) CA2388221C (de)
CY (1) CY1106400T1 (de)
DE (1) DE60032622T2 (de)
DK (1) DK1225870T3 (de)
ES (1) ES2279772T3 (de)
PT (1) PT1225870E (de)
WO (1) WO2001024771A1 (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL143094A0 (en) * 1998-12-02 2002-04-21 Pfizer Prod Inc METHODS AND COMPOSITIONS FOR RESTORING CONFORMATIONAL STABILITY OF A PROTEIN OF THE p53 FAMILY
US7541184B2 (en) * 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
WO2002032378A2 (en) * 2000-10-20 2002-04-25 Tsuneya Ohno Fusion cells and cytokine compositions for treatment of disease
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
EP1337149A4 (de) 2000-10-27 2005-10-12 Irx Therapeutics Inc Vakzinimmuntherapie für immungeschwächte patienten
US20070154399A1 (en) * 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
EP1499355A4 (de) 2001-12-07 2005-10-05 Bayer Pharmaceuticals Corp Verwendung von parapox b2l protein zur behandlung von krebs und modifizierung von immunantworten
CN1774255A (zh) * 2002-02-22 2006-05-17 英特拉舍尔资源有限责任公司 无菌免疫原性非－致瘤性肿瘤细胞组合物和方法
AU2003225793A1 (en) * 2002-03-15 2003-09-29 Baxter Healthcare S.A. Methods and compositions for directing cells to target organs
US20040175373A1 (en) * 2002-06-28 2004-09-09 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
AU2003253684A1 (en) * 2002-06-28 2004-01-19 Xcyte Therapies, Inc. Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20050084967A1 (en) * 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
CA2516783A1 (en) * 2003-02-21 2005-02-03 Hasumi Llc (Dba Shukokai International) Human lymphocyte vaccine adjuvant
EP2234642B8 (de) 2007-11-28 2017-11-01 IRX Therapeutics, Inc. Verfahren zur verstärkung einer immunologischen wirkung
EP2406387A4 (de) * 2009-03-09 2013-04-17 Tvax Biomedical I Llc Zellimmuntherapie für infektionserkrankungen
EP2429585B1 (de) 2009-05-15 2018-04-18 IRX Therapeutics, Inc. Impfstoff-immuntherapie
WO2011072006A1 (en) 2009-12-08 2011-06-16 Irx Therapeutics, Inc. Method of reversing immune suppression of langerhans cells
US10426740B1 (en) 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
ES2771251T3 (es) 2013-03-01 2020-07-06 Us Health Métodos de producción de poblaciones enriquecidas de células T reactivas con tumores a partir de sangre periférica
KR20230148387A (ko) 2015-05-28 2023-10-24 카이트 파마 인코포레이티드 T 세포 요법을 위한 진단 방법
JP7197979B2 (ja) 2015-05-28 2022-12-28 カイト ファーマ インコーポレイテッド Ｔ細胞療法のために患者をコンディショニングする方法
US20190038727A1 (en) * 2015-09-09 2019-02-07 Tvax Biomedical I, Llc Methods for combining adoptive t cell therapy with oncolytic virus adjunct therapy
EP3702447A1 (de) 2015-10-20 2020-09-02 Kite Pharma, Inc. Verfahren zur herstellung von t-zellen zur t-zelltherapie
US11781112B2 (en) * 2016-03-06 2023-10-10 Kareem Thomas Robinson Method of generating antigen-specific immunological memory in a subject that rejects classical vaccines
CR20180461A (es) 2016-04-01 2019-03-05 Kite Pharma Inc Receptores de antígenos quiméricos y células t y métodos de uso
RS63735B1 (sr) 2016-04-01 2022-12-30 Kite Pharma Inc Himerni receptori i postupci njihove upotrebe
TWI795133B (zh) 2016-04-01 2023-03-01 美商凱特製藥公司 Ｂｃｍａ結合分子類及彼等之用途
US20190343954A1 (en) * 2016-12-07 2019-11-14 Transtarget, Inc. Methods and compositions for vaccinating and boosting cancer patients
US11046775B2 (en) 2017-02-14 2021-06-29 Kite Pharma, Inc. CD70 binding molecules and methods of use thereof
TW201837175A (zh) 2017-03-13 2018-10-16 美商凱特製藥公司 用於黑色素瘤之嵌合抗原受體及其用途
BR112019020214A2 (pt) 2017-04-01 2020-04-22 Avm Biotechnology Llc substituição do pré-condicionamento citotóxico antes da imunoterapia celular
JP2020512983A (ja) 2017-04-03 2020-04-30 カイト ファーマ インコーポレイテッドＫｉｔｅ Ｐｈａｒｍａ， Ｉｎｃ 最適化された多機能性ｔ細胞を含むキメラ受容体ｔ細胞を使用する治療
JOP20180042A1 (ar) 2017-04-24 2019-01-30 Kite Pharma Inc نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
MX2019014088A (es) 2017-05-26 2020-02-07 Kite Pharma Inc Metodos de elaboracion y uso de celulas progenitoras mesenquimales embrionarias.
AU2018334279A1 (en) * 2017-09-15 2020-04-02 Kite Pharma, Inc. Methods and systems for performing a patient-specific immunotherapy procedure with chain-of-custody and chain-of-identity biological sample tracking
KR102483755B1 (ko) 2017-09-22 2023-01-03 카이트 파마 인코포레이티드 키메라 폴리펩티드 및 그의 용도
KR20200071753A (ko) 2017-10-18 2020-06-19 카이트 파마 인코포레이티드 키메라 항원 수용체 면역요법제를 투여하는 방법
EP3710471A1 (de) 2017-11-16 2020-09-23 Kite Pharma, Inc. Modifizierte chimäre antigenrezeptoren und verfahren zur verwendung
SG11202006416TA (en) 2018-01-15 2020-08-28 Pfizer Methods of administering chimeric antigen receptor immunotherapy in combination with 4-1bb agonist
US20200390814A1 (en) 2018-02-02 2020-12-17 Arizona Board Of Regents On Behalf Of Arizona State University Dna-chimeric antigen receptor t cells for immunotherapy
CN112534044A (zh) 2018-02-16 2021-03-19 凯德药业股份有限公司 经修饰的多能干细胞及制备和使用方法
KR20210007954A (ko) 2018-04-12 2021-01-20 카이트 파마 인코포레이티드 종양 미세환경의 특징을 이용한 키메라 수용체 t 세포 치료
SG11202011541SA (en) 2018-06-01 2020-12-30 Kite Pharma Inc Chimeric antigen receptor t cell therapy
EP3810780A1 (de) 2018-06-22 2021-04-28 Kite Pharma Eu B.V. Zusammensetzungen und verfahren zur herstellung von gentechnisch veränderten t-zellen
IL280329B1 (en) 2018-08-02 2024-05-01 Kite Pharma Inc Treatment with receptor-antigen chimeric kinetics of T cell expansion and their uses
EP3488851A1 (de) 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapien
EP3632446B3 (de) 2018-10-03 2024-01-24 AVM Biotechnology, LLC Immunoablative therapien
US20220128562A1 (en) * 2018-11-26 2022-04-28 Dana-Farber Cancer Institute, Inc. Biomarkers predictive of cancer cell response to ml329 or a derivative thereof
JP7278379B2 (ja) 2018-11-29 2023-05-19 ヴィネティ インク． 集中型及び分散型の個別化医薬プラットフォーム
BR112021012172A2 (pt) 2018-12-12 2021-08-31 Kite Pharma, Inc. Receptores de antígenos quiméricos e de célula t e métodos de uso
US11321652B1 (en) 2019-02-20 2022-05-03 Vineti Inc. Smart label devices, systems, and methods
EP4249075A3 (de) 2019-05-03 2023-11-08 Kite Pharma, Inc. Verfahren zur verabreichung einer chimären antigen-rezeptor-immuntherapie
CA3143271A1 (en) 2019-06-21 2020-12-24 Kite Pharma, Inc. Tgf-.beta. receptors and methods of use
CN114341348A (zh) 2019-09-03 2022-04-12 艾洛基治疗公司 制备用于t细胞疗法的t细胞的方法
US20230293530A1 (en) 2020-06-24 2023-09-21 Yeda Research And Development Co. Ltd. Agents for sensitizing solid tumors to treatment
IL299911A (en) 2020-08-14 2023-03-01 Kite Pharma Inc Improving immune cell function
WO2022046760A2 (en) 2020-08-25 2022-03-03 Kite Pharma, Inc. T cells with improved functionality
WO2022093925A1 (en) 2020-10-28 2022-05-05 Kite Pharma, Inc. Flow cytometric method for characterization of t-cell impurities
AU2021410635A1 (en) 2020-12-24 2023-06-29 Kite Pharma, Inc. Prostate cancer chimeric antigen receptors
US20220221463A1 (en) 2021-01-10 2022-07-14 Kite Pharma, Inc. T cell therapy
CA3211006A1 (en) 2021-02-20 2022-08-25 Kite Pharma, Inc. Gene markers for sellecting immunotherapies
KR20230155521A (ko) 2021-03-11 2023-11-10 카이트 파마 인코포레이티드 면역 세포 기능의 향상
CA3216056A1 (en) 2021-04-16 2022-10-20 Kite Pharma, Inc. Taci/bcma dual binding molecules
WO2022221126A1 (en) 2021-04-16 2022-10-20 Kite Pharma, Inc. Methods and systems for scheduling a patient-specific immunotherapy procedure
US20220378830A1 (en) 2021-05-14 2022-12-01 Kite Pharma, Inc. Chimeric antigen receptor t cell therapy
KR20240013173A (ko) 2021-05-24 2024-01-30 카이트 파마 인코포레이티드 Nkg2d-기초 키메라 항원 수용체
CN117730100A (zh) 2021-06-08 2024-03-19 凯德药业股份有限公司 Gpc3结合分子
US20230027004A1 (en) 2021-07-01 2023-01-26 Kite Pharma, Inc. Closed-system and method for autologous and allogeneic cell therapy manufacturing
KR20240028503A (ko) 2021-07-02 2024-03-05 카이트 파마 인코포레이티드 세포 요법 응용 분야에 사용되는 유전자 작제물의 유전자 산물에서 변이체를 식별하는 방법
US20230060292A1 (en) 2021-07-26 2023-03-02 Kite Pharma, Inc. Split chimeric antigen receptors and methods of use
EP4377694A1 (de) 2021-07-30 2024-06-05 Kite Pharma, Inc. Überwachung und verwaltung von durch zelltherapie induzierten toxizitäten
US11615874B1 (en) 2021-09-30 2023-03-28 Vineti Inc. Personalized medicine and therapies platform
EP4419559A1 (de) 2021-10-18 2024-08-28 Kite Pharma, Inc. Signalisierungsdomänen für chimäre antigenrezeptoren
US20230296610A1 (en) 2022-02-15 2023-09-21 Kite Pharma, Inc. Predicting adverse events from immunotherapy
US20240091261A1 (en) 2022-08-26 2024-03-21 Kite Pharma, Inc. Immune cell function
US20240165160A1 (en) 2022-10-28 2024-05-23 Kite Pharma, Inc. Efficacy and durable response of immunotherapy
WO2024092227A1 (en) 2022-10-28 2024-05-02 Kite Pharma, Inc. Factors for optimizing immunotherapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766920A (en) 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
WO1988000970A2 (en) 1986-08-08 1988-02-11 Regents Of The University Of Minnesota Method of culturing leukocytes
US5126132A (en) 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US5290551A (en) 1990-05-08 1994-03-01 Thomas Jefferson University Treatment of melanoma with a vaccine comprising irradiated autologous melanoma tumor cells conjugated to a hapten
US5725855A (en) 1991-04-05 1998-03-10 The United States Of America As Represented By The Department Of Health And Human Services Method of treating tumors with CD8+ -depleted or CD4+ T cell subpopulations
US5637483A (en) 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
JPH07504683A (ja) 1992-07-08 1995-05-25 シェリング・コーポレーション Ｇｍ−ｃｓｆのワクチンアジュバントとしての利用
US5650156A (en) * 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
CA2227327A1 (en) * 1995-07-25 1997-02-13 Celltherapy, Inc. Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease

Also Published As

Publication number Publication date
EP1225870B1 (de) 2006-12-27
EP1225870A4 (de) 2003-05-28
DE60032622T2 (de) 2007-12-20
EP1225870A1 (de) 2002-07-31
AU7856700A (en) 2001-05-10
US6406699B1 (en) 2002-06-18
DE60032622D1 (de) 2007-02-08
CA2388221C (en) 2007-12-04
CA2388221A1 (en) 2001-04-12
DK1225870T3 (da) 2007-05-07
CY1106400T1 (el) 2011-10-12
ES2279772T3 (es) 2007-09-01
PT1225870E (pt) 2007-06-11
US20020006409A1 (en) 2002-01-17
WO2001024771A1 (en) 2001-04-12

Similar Documents

Publication Publication Date Title
ATE349198T1 (de) Zusammensetzung und verfahren zur krebs-antigen- immuntherapie
US5030621A (en) Shed melanoma antigen compositions
FI933862A0 (fi) Loesliga ligander foer cd40
ID22689A (id) Metode untuk mengaktifkan sel-sel yang menunjukan-sifat antigen manusia, sel-sel teraktifkan yang menunjukan sifat antigen manusia, dan penggunaannya
WO2002034205A3 (en) Using heat shock proteins to increase immune response
TR200103581T2 (tr) Graft versus host hastalığı tedavisinde CD20' ye karşı antikorların kullanımı.
EP0719150A4 (de) Zellulärer impfstoff und verwendungsmethoden für die behandlung von malignen, soliden tumoren
BR9811037A (pt) Utilização de ligantes mhc classe ii como coadjuvante para vacinação e de lag-3 no tratamento do câncer
ATE389712T1 (de) Krebs immuntherapie mit semi-allogenen zellen
US7402317B2 (en) Anti-cancer vaccine
WO1999003976A3 (en) Method of treating leukocytes, leukocyte compositions and methods of use thereof
US5194384A (en) Method for preparing human meloma vaccine
Gregoire et al. Anti-cancer therapy using dendritic cells and apoptotic tumour cells: pre-clinical data in human mesothelioma and acute myeloid leukaemia
WO2003090687A8 (en) Using heat shock proteins to increase immune response
HUP0204216A2 (en) A new use of antibodies as vaccines
WO2005009397A3 (en) Human lymphocyte vaccine adjuvant
Takigawa et al. Percutaneous Peptide Immunization via Corneum Barrier‐disrupted Murine Skin for Experimental Tumor Immunoprophylaxis
US5993829A (en) Anti-cancer vaccine
CA2754109A1 (en) Infectious disease cellular immunotherapy
RU2000122041A (ru) Способ лечения злокачественных опухолей головного мозга
NL192326B (nl) Werkwijze voor het bereiden van een geneesmiddel, waarbij een gezuiverd, ontgift endotoxine samen met een drager en eventueel andere toevoegingen in een voor therapeutische toediening geschikte vorm wordt gebracht.
RU2000111634A (ru) Способ комбинированной иммунотерапии злокачественных опухолей головного мозга
MX9604099A (es) Inmunoterapia de cancer con linfocitos alogenicos.
SE9704451D0 (sv) New method and compositions for the treatment of autoimmune diseases
Prescott New therapeutic approaches for treating lymphomas

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1225870

Country of ref document: EP